Esomeprazole Magnesium Articles

AstraZeneca may pay Merck & Co $3.3B

20 March 2006

AstraZeneca files suit against generic copiers of Nexium

13 March 2006

AstraZeneca's 4th-qtr profit leaps 30% but firm admits thin pipeline

13 February 2006

AstraZeneca profit leaps 30% but firm admits thin pipeline

6 February 2006

Defending brand pharma against generic threats: study

5 September 2005

Astra Zeneca 2nd-qtr pretax profit leaps 67%

8 August 2005

AstraZeneca sees 2nd-qtr pretax profit leap 67%

1 August 2005

AstraZeneca's GERD drug improves asthma

30 May 2005

AstraZeneca's Nexium sees good results

23 May 2005

AstraZeneca beats forecasts as troubled Crestor sees 1st-qtr sales double

9 May 2005

World retail Rx sales up 6% in 12 mnths to Jan

4 April 2005

Despite a tough year, AstraZeneca's full-year 2004 results fall in target range

7 February 2005

Higher ulcer risk from Plavix, study shows

31 January 2005

Slowdown in revenue growth forecast for AstraZeneca

31 January 2005

Biogenerics to command more than $12B by 2010

17 January 2005

GlaxoSmithKline outperforming UK rival AstraZeneca, say SG Cowen analysts

17 January 2005

AstraZeneca's Nexium OKed for new use in UK

8 November 2004

AstraZeneca's EPS up 56%, sales rise 10%

1 November 2004

World drug sales up 8% in year to August 2004

25 October 2004

AstraZeneca flies the flag at business review despite Exanta and Galida woes

11 October 2004

EXPO study reinforces supremacy claims for AstraZeneca's Nexium among PPIs

11 October 2004

Stock Commentary - Europe

4 October 2004

AstraZeneca's Nexium gets OK for new uses

27 September 2004

Global Rx drug prices up 8% in year to June 2004

23 August 2004

AstraZeneca's 2nd-qtr sales jump 19%

2 August 2004

Stock Commentary - Europe

26 July 2004

AstraZeneca's 1st-qtr sales pass $5 billion

3 May 2004

Merck & Co reports 5% drop in 1st-qtr income

3 May 2004

71% of pharma firms have fought generics with legal battles

26 April 2004

Global Rx sales up 9% in 2003, with US market rising 11%, reports IMS

29 March 2004

AstraZeneca launches IV formulation of Nexium in UK

22 March 2004

US Rx drug sales up 11.5% in 2003, growth sustained by new products, says IMS

23 February 2004

AstraZeneca forecasts sharp rise in earnings but shares slip on mediocre Crestor sales

9 February 2004

AstraZeneca looking to expand Nexium label

9 February 2004

MS analysts revise AstraZeneca's outlook

26 January 2004

Nexium IV for EU

30 November 2003

World retail drug sales grew 8% in year to November 2003, says IMS

30 November 2003

US market developments in 2002-3 and the rise of generics; CBI meeting

8 December 2003

New results for AstraZeneca's Nexium

17 November 2003

AstraZeneca beats expectations as strong sales drive third-quarter growth

3 November 2003

US DTC ad spend, and response, levels off

20 October 2003

AstraZeneca's Crestor off to strong start in USA; overall performance on track

13 October 2003

Stock Commentary - Europe

8 September 2003

AstraZeneca raises full-year earnings guidance on comforting 2nd-qtr results

4 August 2003

AstraZeneca raises full-year earnings guidance

28 July 2003

Maine's Medicaid Rx preferred list launched

21 July 2003

AstraZeneca/P&G's Prilosec OTC cleared by FDA for frequent heartburn

30 June 2003

Crestor advisory panel raises fears of delay

26 May 2003

AstraZeneca's Iressa gets FDA approval for third-line use in NSCLC

12 May 2003

Profits down at AstraZeneca as Prilosec sales plummet, but Nexium turnover soars

5 May 2003

Schwarz lifts forecasts on strong generic sales

14 April 2003

2002 world pharma sales growth: slower but still healthy, says IMS

24 March 2003

USA's FTC probing Elan, Skye and AstraZeneca

10 March 2003

High US co-pays "are driving PPI switches"

17 February 2003

Despite Losec competition AstraZeneca reports 7% hike in 2002 earnings

10 February 2003

Prilosec market share slumps 50% in USA

20 January 2003

10 most effective US DTC television ads

5 August 2002

AstraZeneca sales rise 6.9% in 2nd quarter

5 August 2002

AstraZeneca wins round in Prilosec patent lawsuit

1 July 2002

Stock Commentary - Europe

10 June 2002

Double-digit growth rates elude most blockbuster firms, says Datmonitor

27 May 2002

Solid set of results at AstraZeneca, but Crestor approval delay

6 May 2002

Arimidex launched for early breast cancer

11 March 2002

AstraZeneca invests $66 million in Swedish production site

11 March 2002

Nexium tops rival in GERD maintenance trial

4 March 2002

AstraZeneca confident about overcoming loss of Prilosec revenues

11 February 2002

Solid set of results at AstraZeneca as Nexium continues to perform well

4 February 2002

Expensive new GERD drugs "actually more cost-effective"

28 January 2002

Schering-Plough ends troubled year with a lift as Clarinex gets US approval

7 January 2002

Schering-Plough ends troubled year with a lift as Clarinex gets US approval

27 December 2001

AstraZeneca highlights key product growth over the next five years

6 December 2001

"Robust" year for AstraZeneca

5 December 2001

Date set for Prilosec patent suit in USA

25 October 2001

Solid results for AstraZeneca as Nexium continues to capture market share

24 October 2001

Big pharma continuing to dominate top-selling drugs market, says IMS

18 October 2001

Nexium comparative data provides further boost to AstraZeneca

10 October 2001

Reprieve for AstraZeneca as FDA delays Andrx' generic omeprazole

5 October 2001

AstraZeneca's brave move to go solo with Crestor applauded

27 July 2001

AstraZeneca sales rise 8%, Nexium doing well

26 July 2001

Stock Commentary - Europe

31 May 2001

Nexium makes strong start in USA

24 May 2001

AstraZeneca gets six months' Prilosec grace

3 May 2001

AstraZeneca hit by slip in Losec sales

26 April 2001

Stock Commentary - Europe

1 March 2001

Nexium approved with broad indications in USA; launch slated for March

21 February 2001

AstraZeneca issues sales and profits slowdown warning

8 February 2001

Stock Commentary - New York

18 January 2001

Healthy harvest of New Chemical Entities in 2000

2 January 2001

AstraZeneca says pessimism surrounding Nexium take-up is unfounded

13 December 2000

Stock Commentary - Europe

23 November 2000

AstraZeneca Nexium sales in Sweden rise 56% in one month

22 November 2000

Healthy revenue increase at Eisai

14 November 2000

AstraZeneca predicting less than double-digit growth for full-year 2000

25 October 2000

Blow for AstraZeneca as FDA panel votes against OTC omeprazole at this time

23 October 2000

AstraZeneca - up with events

20 October 2000

US market growth of 16.9% driving world pharmaceutical sales, says IMS

18 October 2000

Stock Commentary Tokyo

12 October 2000

AstraZeneca's Nexium is "approvable"

11 October 2000

Japan's MHW instructs Takeda to issue emergency notice over Actos

5 October 2000

Stock Commentary Europe

21 September 2000

Showing 101-200 of 224 articles

Go to beginningPreviousNextGo to end